研究报告 |
|
|
|
|
抗α2δ1/CD3双特异性抗体的制备和功能的初步研究 * |
杨笑莹1,李梦2,赵威2,唐敏1,张志谦1,**() |
1 重庆医科大学检验医学院 临床检验诊断学教育部重点实验室 重庆 400016 2 北京大学肿瘤医院细胞生物室 北京 100142 |
|
Preparation and Preliminary Characterization of Anti-α2δ1/CD3 Bispecific Antibody |
YANG Xiao-ying1,LI Meng2,ZHAO Wei2,TANG Min1,ZHANG Zhi-qian1,**() |
1 Key Laboratory of Clinical Laboratory Diagnostics of Ministry Education, Faculty of Laboratory Medicine, Chongqing Medicine University, Chongqing 400016, China 2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cell Biology,Peking University Cancer Hospital and Institute, Beijing 100142, China |
引用本文:
杨笑莹,李梦,赵威,唐敏,张志谦. 抗α2δ1/CD3双特异性抗体的制备和功能的初步研究 *[J]. 中国生物工程杂志, 2020, 40(7): 9-14.
YANG Xiao-ying,LI Meng,ZHAO Wei,TANG Min,ZHANG Zhi-qian. Preparation and Preliminary Characterization of Anti-α2δ1/CD3 Bispecific Antibody. China Biotechnology, 2020, 40(7): 9-14.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2001045
或
https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I7/9
|
[1] |
Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 2015,65(2):87-108.
doi: 10.3322/caac.21262
|
[2] |
Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology, 2010,52(2):762-773.
doi: 10.1002/hep.23725
pmid: 20564355
|
[3] |
Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med, 2011,17(3):313-319.
doi: 10.1038/nm.2304
pmid: 21386835
|
[4] |
Visvader J, Lindeman G. Cancer stem cells: current status and evolving complexities. Cell Stem Cell, 2012,10(6):717-728.
doi: 10.1016/j.stem.2012.05.007
|
[5] |
Zhao W, Wang L P, Han H B, et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit. Cancer Cell, 2013,23(4):541-556.
doi: 10.1016/j.ccr.2013.02.025
|
[6] |
Thakur A, Lum L G. “NextGen” biologics: bispecific antibodies and emerging clinical results. Expert Opin Biol Ther, 2016,16(5):675-688.
doi: 10.1517/14712598.2016.1150996
pmid: 26848610
|
[7] |
Kontermann R E, Brinkmann U. Bispecific antibodies. Drug Discov Today, 2015,20(7):838-847.
doi: 10.1016/j.drudis.2015.02.008
pmid: 25728220
|
[8] |
Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 2008,321(5891):974-977.
doi: 10.1126/science.1158545
pmid: 18703743
|
[9] |
Cioffi M, Dorado J, Baeuerle P A, et al. EpCAM/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clinical Cancer Research, 2011,18(2):465-474.
doi: 10.1158/1078-0432.CCR-11-1270
pmid: 22096026
|
[10] |
Choi B D, Kuan C T, Cai M, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA, 2013,110(1):270-275.
doi: 10.1073/pnas.1219817110
pmid: 23248284
|
[11] |
Torisu-Itakura H, Schoellhammer H F, Sim M S, et al. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunol, 2011,34(8):597-605.
|
[12] |
Xu X L, Xing B C, Han H B, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient’s primary and recurrent tumor. Carcinogenesis, 2010,31(2):167-174.
pmid: 19897602
|
[13] |
Shalaby M R. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. Journal of Experimental Medicine, 1992,175(1):217-225.
pmid: 1346155
|
[14] |
Zhu Z, Carter P. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J Immunol, 1995,155(4):1903-1910.
pmid: 7636241
|
[15] |
Davis D M, Dustin M L. What is the importance of the immunological synapse. Trends Immunol, 2004,25(6):323-327.
doi: 10.1016/j.it.2004.03.007
pmid: 15145322
|
[16] |
Dustin M L, Depoil D. New insights into the T cell synapse from single molecule techniques. Nat Rev Immunol, 2011,11(10):672-684.
pmid: 21904389
|
[17] |
Asano R, Ikoma K, Shimomura I, et al. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody. J Biol Chem, 2011,286(3):1812-1818.
doi: 10.1074/jbc.M110.172957
pmid: 21097496
|
[18] |
Junttila T T, Li J, Johnston J, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res, 2014,74(19):5561-5571.
doi: 10.1158/0008-5472.CAN-13-3622-T
pmid: 25228655
|
[19] |
Sun L L, Ellerman D, Mathieu M, Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. [2020-6-20]. https://stm.sciencemag.org/content/7/287/287ra70/tab-pdf#.
|
[20] |
Liao W, Lin J X, Leonard W. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity, 2013,38(1):13-25.
doi: 10.1016/j.immuni.2013.01.004
pmid: 23352221
|
[21] |
Malek T R. The biology of interleukin-2. Annu Rev Immuno, 2008,26(1):453-479.
doi: 10.1146/annurev.immunol.26.021607.090357
|
[22] |
Dunn G P, Koebel C M, Schreiber R D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol, 2006,6(11):836-848.
doi: 10.1038/nri1961
pmid: 17063185
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|